You are in the accessibility menu

Please use this identifier to cite or link to this item: http://acervodigital.unesp.br/handle/11449/113328
Title: 
Semliki Forest Virus as a Vector: Pros and Cons for Its Use in Biopharmaceuticals Production
Author(s): 
Institution: 
  • Universidade de São Paulo (USP)
  • Universidade Estadual Paulista (UNESP)
  • Instituto Butantan
  • Inst Pesquisas Tecnol Estado Sao Paulo SA
ISSN: 
1516-8913
Sponsorship: 
  • Fundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP)
  • Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq)
Sponsorship Process Number: 
FAPESP: 10/52521-6
Abstract: 
The number of biopharmaceuticals for medical and veterinarian use produced in mammalian cells is increasing year after year. All of them are obtained by stable recombinant cell lines. However, it is recognized that transient gene expression produces high level expression in a short time. In that sense, viral vectors have been extensively used for producing recombinant proteins on lab-scale. Among them, Semliki Forest virus is commonly employed for this purpose. This review discusses the main aspects related to the use of Semliki Forest virus technology as well as its advantages and drawbacks which limit currently its utilization in biopharmaceutical industry on large-scale.
Issue Date: 
1-Sep-2013
Citation: 
Brazilian Archives of Biology and Technology. Curitiba-parana: Inst Tecnologia Parana, v. 56, n. 5, p. 859-866, 2013.
Time Duration: 
859-866
Publisher: 
Inst Tecnologia Parana
Keywords: 
  • BHK-21
  • Large-scale bioprocesses
  • Mammalian cells
  • Recombinant proteins
  • SFV
  • Transient expression
Source: 
http://dx.doi.org/10.1590/S1516-89132013000500018
URI: 
Access Rights: 
Acesso aberto
Type: 
outro
Source:
http://repositorio.unesp.br/handle/11449/113328
Appears in Collections:Artigos, TCCs, Teses e Dissertações da Unesp

There are no files associated with this item.
 

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.